Type : Contract
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES Solicitation ID/Procurement Identifier: 75N93022R00009 Ultimate Completion Date: Fri Sep 29 17:00:00 GMT 2028
VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES Solicitation ID/Procurement Identifier: 75N93022R00009 Ultimate Completion Date: Fri Sep 29 17:00:00 GMT 2028
Award Notice
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. As one component of the VRC’s research, the VRC, NIAID, NIH has been investigating the use of novel adjuvants in our vaccine development program for HIV, influenza and other viral vaccines, and has found the “Adjuplex brand” of adjuvant from Advanced BioAdjuvants LLC (ABA) to be superior to other adjuvants.
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. As one component of the VRC’s research, the VRC, NIAID, NIH has been investigating the use of novel adjuvants in our vaccine development program for HIV, influenza and other viral vaccines, and has found the “Adjuplex brand” of adjuvant from Advanced BioAdjuvants LLC (ABA) to be superior to other adjuvants.
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. As one component of the VRC’s research, the VRC, NIAID, NIH has been investigating the use of novel adjuvants in our vaccine development program for HIV, influenza and other viral vaccines, and has found the “Adjuplex brand” of adjuvant from Advanced BioAdjuvants LLC (ABA) to be superior to other adjuvants.